Suchergebnisse - "Cook, Gordon"

PubPharm (409)

51

COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

enthalten in: British Journal of Haematology | 2022

von Ramasamy, K. | Sadler, R. | Jeans, S. | +15

52

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

enthalten in: British Journal of Haematology | 2022

von Chan, W. | Counsell, N. | Tute, R. | +17

53

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19 : disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy

enthalten in: British Journal of Haematology | 2022

von Booth, S. | Curley, H. | Varnai, C. | +32

54

Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response

enthalten in: British Journal of Haematology | 2022

von Ramasamy, K. | Sadler, R. | Jeans, S. | +17

55

COVID symptoms, testing, shielding impact on patient reported outcomes and early vaccine responses in individuals with multiple myeloma

enthalten in: bioRxiv.org | 2021

von Ramasamy, K. | Sadler, R. | Jeans, S. | +15

56

COVID-19 vaccination in patients with multiple myeloma : a consensus of the European Myeloma Network

enthalten in: The Lancet. Haematology | 2021

von Ludwig, H. | Sonneveld, P. | Facon, T. | +33

57

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes : Results from 3894 Patients in the Myeloma XI Trial

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Bird, S. | Cairns, D. | Menzies, T. | +12

58

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

enthalten in: Haematologica | 2021

von Weinhold, N. | Salwender, H. | Cairns, D. | +15

59

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

60

Ixazomib-lenalidomide-dexamethasone in routine clinical practice : effectiveness in relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2021

von Hájek, R. | Minařík, J. | Straub, J. | +33